What You Should Know: Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.Taiwania Capital and Debiopharm Innovation Fund co-led the round, with participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. Other new investors include P5 Health
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
NVIDIA Unveils Generative AI Service to Advance Life Sciences R&D
What You Should Know: - NVIDIA today announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics. - Part of NVIDIA AI Foundations, the new BioNeMo™ Cloud service offering — for both AI model training and inference — accelerates the most time-consuming and costly stages of drug discovery. It
Read More
Protai Raises $20M to Build an Oncology Drug Discovery Pipeline
What You Should Know: - Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced a $12 million extension of its seed round, bringing the total amount to $20M. - The round includes existing investors Grove Ventures and Pitango Healthcare and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai’s oncology drug discovery pipeline, expand data
Read More
Tempus, Pfizer Partner to Advance Oncology Therapeutic Development
What You Should Know: - Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery and development in oncology. - Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology. -
Read More
Report: Pharma R&D ROI Falls to Lowest Level in 13 Years
What You Should Know: - Deloitte Centre for Health Solutions releases its thirteenth annual report, ‘Seize the Digital Momentum: Measuring the return from pharmaceutical innovation 2022’ that explores the performance of the biopharmaceutical industry (bio Pharma) and its ability to generate returns from investment in innovative new medicines. - Since 2021, much of the world has successfully adjusted to life where COVID-19 is more endemic as vaccines and treatments reduced the risk and
Read More
BenchSci Launches ‘Map’ of Biology Research Platform for Pharmaceutical Research
What You Should Know: - BenchSci, a Canadian-based tech company and leader in AI solutions for drug discovery recently launches a Google-backed 'map' of biology research platform, ASCEND™ by BenchSci, to understand the underlying biology. - The patented machine learning platform reads millions of published and previously hidden experiment external and internal data sources to create a map that allows scientists to more quickly (50% more) and accurately understand the biological
Read More
7 Life Sciences Executive Predictions to Watch in 2023
Tracy Curley, CFO and interim CEO at iSpecimen Focusing on the macroeconomic environment, which remains impacted by the lingering COVID-19 pandemic, there continues to be uncertainty about the strength of the global, Asia Pacific, UK and US economies. High-interest rates and a potential recession remain a concern for all market participants. At ISPC, we are closely monitoring the pace of specimen transactions. We believe that this industry can be resilient through a continued economic
Read More
Merck Invests in Gesund, Launches Medical AI Platform on AWS
What You Should Know: - Gesund, the company ensuring that medical artificial intelligence (AI) is safe and effective for all, today announced the securing of a strategic investment from Merck as well as a launch of a new commercial platform on Amazon Web Services Marketplace. - While terms of the investment are not being disclosed, the news signals support for the company's approach as it launches a first of its kind commercial platform on Amazon Web Services Marketplace, immediately
Read More
Analysis: RSNA 2022: Predictions vs Reality
Much has already been written about attendance at RSNA, but from a first-hand perspective, RSNA 2022 could be regarded as a step back toward “normal”. Amongst mostly bustling halls, vendors reported very positive feedback on the volume and quality of customer meetings, with one prominent global imaging vendor citing “We’re signing deals here at the show again – things are looking up”. Against this positive backdrop, however, the stark challenges facing radiology in a post-COVID world were
Read More
Vevo Launches with $12M to Scale Vivo Data Generation to Discover Better Drugs
What You Should Know: - Vevo Therapeutics, an SF-based biotechnology company, launched today with a $12M seed round led by General Catalyst and Wing Venture Capital using its Mosaic in vivo drug discovery platform and next-generation AI models to uncover better drugs for more patients. - Vevo is the first platform to make in vivo data generation scalable with single-cell precision + will create the world’s largest atlas of how drugs interact with patient cells. In a single in vivo
Read More
